Exothera

🧬dsRNA in mRNA Vaccines: The Silent Threat to Potency & Safety Residual double-stranded RNA (dsRNA) in mRNA vaccines can impact potency and immunogenicity, making accurate detection essential. Regulatory agencies, including USP, emphasize the need for validated analytical methods. In our latest whitepaper, we explore the development of an in-house ELISA for dsRNA detection, tackling key challenges like assay calibration, matrix interference, and reagent variability. Learn how our optimized approach enhances specificity, sensitivity, and reproducibility in mRNA vaccine development. 📥 Download the full whitepaper here: https://lnkd.in/ew_QP5aq #mRNAvaccines #dsRNA #ELISA #Biotech #CDMO #VaccineDevelopment

🚀 Behind every breakthrough, there’s a team! Meet Vanessa Daubront Yumar, our DSP & Formulation Manager, who’s been helping shape bioprocessing at Exothera for the past years. From Venezuela to Belgium, she took a leap for science—and never looked back. But what drives her passion for DSP? Let’s hear it from her! 👇 ➡️ Swipe through to meet Vanessa! #MeetTheTeam #Bioprocessing #CDMOExperts #Exothera

🚨 New Report Alert: Tackling Immunogenicity in AAV Gene Therapy! 🚨 Immunogenicity remains one of the biggest hurdles in AAV gene therapy clinical trials—but how can we mitigate these risks to improve patient outcomes? At the ESGCT 2024 Conference, our CTO, Hanna P. Lesch joined an expert panel to discuss how the right bioanalytical strategies and industry collaboration can help overcome immunogenicity challenges in rAAV-based therapies. 🔎 Key insights from the roundtable: ✅ Immunogenicity risk factors in rAAV therapies are complex and wide-ranging ✅ Accurate bioanalytical strategies are essential for assessing risk factors ✅ In vivo and in vitro models have limitations—industry partnerships can help bridge the gap ✅ Laboratory service providers must work as true partners to navigate regulatory and clinical challenges ✅ Guidance must evolve alongside advancements in AAV-based therapies 📢 The full report is now available! Dive into the latest industry perspectives and strategies: 👉 Read the report: https://lnkd.in/dH-Es-cn At Exothera, we’re dedicated to advancing viral vector manufacturing and helping AAV developers navigate the complexities of immunogenicity risks. Learn more about our expertise: https://lnkd.in/dP6uYMdA 💬 What do you think? How is your team addressing immunogenicity in AAV gene therapy? Let’s discuss in the comments! 👇 #GeneTherapy #AAV #Immunogenicity #Biomanufacturing #ESGCT2024 #Exothera #AdvancedTherapies

We’re honored and thrilled to share that we are among the nominees for the Best Production / Process Development Award at the ViE Awards during the The World Vaccine Congress! 🎉 This nomination is a testament to our team’s hard work and commitment, and we are truly grateful for the chance to make a difference and help shape the future of vaccine production. If our work has made a difference to you, we’d love your support—please consider voting for us! 🏆 🔗 https://lnkd.in/eiFduPvh #ViEAwards #WVCDC #ProcessDevelopment #Vaccines #Teamwork

🔬 Key Considerations for Scaling Advanced Therapies The landscape of RNA and viral vector-based therapies is evolving rapidly, bringing exciting opportunities—but also significant manufacturing challenges. For biotech and pharma teams advancing mRNA vaccines, gene therapies, or cell therapies, here are critical factors to consider: ✅ Quality & Consistency – Regulatory expectations for advanced therapies are stringent. Ensuring batch-to-batch reproducibility with robust analytical methods is crucial for clinical and commercial success. ⚡ Speed & Flexibility – mRNA vaccines and personalized medicines require accelerated production timelines. Manufacturing agility is key to meeting patient needs without compromising quality. 🔄 Process Optimization – Whether scaling viral vector production or fine-tuning an RNA platform, early process development decisions impact long-term scalability and cost efficiency. 🛠️ Regulatory Alignment – From CMC strategies to evolving guidelines, staying ahead of global regulatory requirements is critical to smooth market entry. As the field progresses, collaboration across biotech, pharma, and CDMOs will be essential to overcoming these challenges and ensuring innovative therapies reach patients efficiently. What other key factors do you consider when bringing an advanced therapy to market? Let’s discuss. 👇 #AdvancedTherapies #mRNA #ViralVectors #GeneTherapy #Biotech #CellAndGeneTherapy #Manufacturing

Exciting advancements in cancer immunotherapy! GSK’s £50 million partnership with the University of Oxford is driving new research into mRNA-based vaccines targeting tumor-specific neoantigens—aiming to stop cancer before it takes hold. Personalized cancer vaccines demand not just innovation but also high-quality, rapid production to meet individual patient needs. As a CDMO, we are committed to enabling these breakthroughs with precision manufacturing and agile supply chains. The future of oncology is personal, and we’re proud to support its evolution. Read more here: https://lnkd.in/earQiWra #mRNA #PersonalizedMedicine #CDMO #Oncology #Biotech

💌💙 We’re feeling the love this Valentine’s Day... and we've got our eye on some incredible biotech partners! 💙💌 This year, we’re looking to form next-level partnerships in the RNA and viral vector space. 🧬 Let’s create something special together! ✨ Big Pharma (GSK Pfizer Novartis Sanofi, are you ready to collaborate to bring groundbreaking therapies to patients worldwide? 💊🌍 ✨ mRNA Therapeutics Leaders ( BioNTech SE Moderna CureVac, should we script the next chapter of mRNA innovation together? ✍️🧬 ✨ To the other biotech innovators out there, how about we accelerate life-changing medicines, hand in hand? 💉🤝 Let’s make this Valentine’s Day the start of a partnership that changes the game. If you're ready to join forces, we’re all about accelerating innovation with the right partners. Together, we can deliver life-saving treatments faster, better, and more efficiently! 💖 #ValentinesDay #RNA #ViralVectors #CDMO #InnovationInBiotech #PartnerForSuccess #LifeChangingScience

🧬 mRNA Stability & Formulation: The #1 Challenge in RNA Therapeutic Manufacturing Last month, we ran a poll asking what the biggest hurdle is in RNA therapeutic manufacturing. The results were clear: stability & formulation came out on top. And it’s no surprise. ⚠️ mRNA is inherently unstable. ⚠️ Formulation impacts efficacy, delivery, and shelf life. ⚠️ Cold chain dependency creates logistical challenges. 📢 To dive deeper into how to tackle mRNA stability & formulation challenges, we’ve put together a short carousel—check it out! 👇 What are your biggest challenges in RNA manufacturing? Let’s discuss in the comments! #mRNATherapeutics #CDMO #DrugDevelopment

🎥 Women in Science & the Power of Support 👩🔬💙 At Exothera, we celebrate the brilliant women driving innovation in our labs and beyond. But supporting women in science isn’t just about their work—it’s about empowering them at every stage of their journey. In this short video, Catherine, head of production at Exothera, reflects on her journey as a woman in science and the importance of workplace support at every stage of life—including moments of personal growth. 💡👶 📢 This International Day of Women & Girls in Science, let’s champion workplaces where women can thrive—personally and professionally. Tag an inspiring woman in STEM and celebrate their impact! 👇 #WomenInScience #CDMO #STEM

🔬 Quality isn’t just a step in the process—it’s the foundation of everything we do. In viral vector and RNA manufacturing, precision, consistency, and compliance are critical to delivering safe and effective therapies. But what does quality assurance (QA) and quality control (QC) look like behind the scenes? 💡 From GMP compliance to cutting-edge analytical technologies, we’ve built a robust quality framework to ensure the highest standards at every stage. Swipe through our latest carousel to see how we make quality a reality! 🚀👇   https://exothera.world #CDMO #Biomanufacturing #QualityAssurance #QualityControl #GMP #ViralVector #RNA #GeneTherapy